Completed PHASE2 INTERVENTIONAL 1-arm NCT00133991

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma

Sponsor: National Cancer Institute (NCI)

Interventions Cyclophosphamide Cytarabine Filgrastim Hydrocortisone Leucovorin Methotrexate Prednisone Rituximab Vincristine

Updated 7 times since 2017 Last updated: Sep 13, 2018 Started: Jul 31, 2005 Primary completion: Aug 31, 2011 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00133991, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Oct 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States
• Philadelphia, United States